How It Works
Making matches on the molecular level
The one-size-fits-all approach to mental health treatment works for no one. IDgenetix is a comprehensive pharmacogenomics (PGx) test that provides personalized medication profiles, tailored to a patient’s unique DNA. The test accounts for more factors that can influence a patient’s response to medication than any other PGx test.
PGx testing helps to determine a person’s metabolic phenotype - how their genes will impact their metabolism of drugs. Some people have genes that cause them to metabolize medicine very rapidly. Individuals with gene mutations associated with rapid metabolism may require higher doses of a medicine for it to have the same effect as someone with a lower metabolism. They may also experience fewer side effects.
IDgenetix PGx test integrates an individual report based on:
97% of individuals carry actionable genetic variants affecting drug metabolism
52% of patients take more than one medication
Lifestyle factors and environment
Lifestyle and demographic factors may affect a patient’s ability to metabolize medications or increase the risk of side effects
Create personalized medication profiles
The IDgenetix test includes 127 medications and 26 drug classes in 10 disease indications. Bioinformatics algorithmic screening assesses and interprets complex factors to generate an easy-to-read report, personalized to the patient.
- 10 conditions profiled:
- ADHD, Anxiety, Arthritis, Bipolar Disorder, Depression, Migraine, Musculoskeletal Pain, Neuropathic Pain, Psychosis, Seizure Disorder
- 26 drug classes
- 127 medications
- 15 genes
- 73 alleles
Improved response and remission rates in patients receiving IDgenetix-guided medication management for major depressive disorder20 May 2023
In the study, patients whose medication management was guided by IDgenetix achieved a 35% increase in medication response and a 64% increase in remission compared to patients whose medication was not guided by the test
Cao F, Maciel A, Wosnik K, et al.
IDgenetix-Guided Medication Management for Major Depressive Disorder: Confirmation of Randomized Controlled Trial Outcomes by Real-World Evidence09 Nov 2023
This study compared the clinical outcome results from Bradley et al. (2018) with real-world evidence. Patient response and remission rates strongly aligned between both studies.
Cao F, Hanson A, Cook R
The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients With Major Depressive Disorder in a Randomized Controlled Trial.06 Sep 2023
In this study, drug-drug interactions accounted for 32% of all IDgenetix-guided drug recommendations, and lifestyle factors accounted for 11%. Incorporating these non-genetic factors in IDgenetix testing significantly impacts the number of drug recommendations and improves remission rates in patients with moderate to severe depression.
Cao F, Hanson A, Cook R, et al.
Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysis01 Mar 2023
Pharmacogenomic (PGx) testing may increase the probability of remission and response in patients with major depressive disorder (MDD) undergoing pharmacotherapy.
Bunka M, et al.
Clinically validated in depression and anxiety
In a randomized controlled trial (RCT), patients with depression and patients with anxiety whose doctors received IDgenetix testing guidance had a better chance of responding to medication and achieving remission.
Patients with severe depression who received IDgenetix-guided treatment:
- Were 2x more likely to respond to treatment
- Had 2.5x higher rates of remission
Patients with anxiety who received IDgenetix-guided treatment were more likely to respond to treatment.
Randomized Controlled Trial (RCT)
- 685 participants with depression and/or anxiety
- Treated by Psychiatrists, Internal Medicine, OBGYN, Family Medicine
- 20 independent clinical sites
- 4, 8 and 12-week efficacy using HAM-D